Serum uric acid levels of patients with multiple sclerosis and other neurological diseases

¹ Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou 510630, Guangdong Province, People's Republic of China
² State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center of Sun Yat-Sen University, 54 Xianlie Road, Guangzhou 510060, Guangdong Province, People's Republic of China
³ Department of Neurology, The First Affiliated Hospital of Sun Yat-Sen University, 89 Zhongshaner Road, Guangzhou 510080, Guangdong Province, People's Republic of China

^* To whom correspondence should be addressed.

	Abstract

The serum uric acid (UA) levels were measured in 112 patients with multiple sclerosis (MS) and 794 patients with different types of other neurological diseases (OND) or healthy control group. Serum UA levels, along with relevant clinical parameters of MS and OND, were also investigated. MS patients had significantly lower UA levels than those with transient ischemia attack (344.6±130.6 µmol/L, P=0.000), cerebral hemorrhage (311.9±104.7 µmol/L, P=0.000), cerebral infarction (291.3±101.6 µmol/L, P=0.014) and the healthy control group (312.1±92.8 µmol/L, P=0.000). MS patients had significantly higher serum UA levels than those with cryptococcus meningitis or meningoencephalitis (178.9±107.0 µmol/L, P=0.000) and tuberculous meningitis or meningoencephalitis patients (175.7±99.9 µmol/L, P=0.000). There were no significant differences in UA levels between patients with MS and those with facial neuritis, viral meningitis or encephalitis, pulmonary tuberculosis, polymyositis or dermatomyositis, myasthenia gravis, subarachnoid hemorrhage, migraine, Guillain–Barre syndrome and myelitis. In addition, UA levels were independently correlated with gender and duration of MS, but neither with MRI activity, disability nor subtypes of the disease in MS patients. Our data suggest that UA has two biphasic functions: neuroprotective and injurious. Our studies may help physicians to deal with conditions having abnormal UA levels. Multiple Sclerosis 2007; 00: 00–00. http://msj.sagepub.com

Key Words: multiple sclerosis; neuroprotection; other neurological diseases; treatment; uric acid

First published on October 17, 2007, doi:10.1177/1352458507082143

Multiple Sclerosis 2008;14:188.

A more recent version of this article appeared on March 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?